Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema

Lin, Tai‐Chi; Chung, Yu-Chien; Hsu, Tsui‐Kang; Huang, Hsiao‐Ping; Huang, Yiming; Chou, Y.C.; Chao, Chen-Yu; Tseng, Po-Chen

doi:10.1007/s00592-021-01824-5

Cited by 11 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lin et al compared the combination of DEX implant and a ibercept with a ibercept treatment. In their study, it was observed that the patients had previously received treatment (the eyes had previously received anti-VEGF injection and/or laser treatment) and also the 6-months follow-up period was shorter compared to our study [22]. This stands out as one of the superior aspects of our study.…”

Section: Discussionmentioning

confidence: 58%

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Ozsaygılı,

Bayram

2024

Int Ophthalmol

View full text Add to dashboard Cite

To compare the anatomical and functional outcomes of the combination of a ibercept and dexamethasone implant (CT) against a ibercept monotherapy (AM) in treatment-naive diabetic macular edema (DME) patients with serous macular detachment and hyperre ective foci. MethodsThis study included 82 eyes of 82 patients with treatment-naive DME who completed the follow-up period of 12 months. All patients had optical coherence tomography (OCT) biomarkers of an in ammatory DME phenotype. Patients were consecutively selected and classi ed into two groups. The CT group consisted of 39 eyes treated with a ibercept therapy and initially combined with a single-dose dexamethasone implant. The AM group consisted of 43 eyes treated with a ibercept alone. The primary outcome measures of the study were the mean reduction of the central macular thickness (CMT) and total macular volume parameters (TMV) and improvement in best-corrected visual acuity (BCVA). ResultsIn both groups, the patient characteristics including age, gender, duration of diabetes, HbA1c levels, phakic percentage, and diabetic retinopathy status were similar (P > 0.05). The mean reduction in CMT and TMV was signi cantly higher in the CT group compared to the AM group (P < 0.001 and P = 0.002, respectively), while mean letter gains were not signi cantly higher (P = 0.240) at the end of the study. In the CT group, 8 eyes (20.5%) showed a transient IOP increase, and 18% of patients developed cataract. In subgroup analysis, the mean letter gain in pseudophakic eyes was signi cantly higher (12.5 in the CT vs. 9.3 in the AM group, P = 0.027). ConclusionThe CT, where in ammation is prominent, can provide faster recovery. The pseudophakic eyes seem to be the ideal patient group for CT.

show abstract

Section: Discussionmentioning

confidence: 58%

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Ozsaygılı,

Bayram

2024

Int Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Bevacizumab 30 63.20 14/16 30/0 N/A 0.83 434.42 2. Ozurdex + Bevacizumab 35 64.34 12/17 31/4 0.82 462.34 Lin et al 32 Retrospective 2021 6 Not persisted DME 1.Aflibercept 50 63.4 26/14 16/34 7.4 0.63 420.6 2. Ozurdex + Aflibercept 52 65.1 20/21 29/23 7.5 0.64 433.8 Maturi et al 36 RCT 2015 12 Not persisted DME 1.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Chi

Kang

Huang

2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included randomized control trials (RCTs) and non-randomized control trials (Non-RCTs) before December 2021 that compare the efficacy of Ozurdex-related therapyand anti-VEGF therapy. We searched PubMed, Cochrane Library, and EMBASE. The quality of the included studies was assessed carefully. 30 studies were included. Regarding BCVA change, the overall result revealed no significant differences between Ozurdex and anti-VEGF therapies in patients with nonresistant DME, but Ozurdex group had significantly more VA improvement than anti-VEGF therapies in patients with resistant DME (MD 0.12, 95% CI 0.02–0.21). In terms of central retinal thickness (CRT) decrease, there was a significant difference between Ozurdex therapy and anti-VEGF therapy in patients with nonresistant DME (MD 48.10, 95% CI 19.06–77.13) and resistant DME (MD 65.37, 95% CI 3.62–127.13). Overall, Ozurdex therapy resulted in significantly greater VA improvement and CRT decrease than anti-VEGF therapy in resistant DME patients. Ozurdex therapy was not inferior to anti-VEGF therapy in patients with nonresistant DME.

show abstract

“…In addition, the growing number of annual citations also re ects the growing in uence of related publications. On the one hand, this growth trend is due to the endless stream of DME treatment methods: including ranibizumab, bevacizumab, a ibercept, dexamethasone and other medicine [34][35][36] ; on the other hand, it is due to the gradual increase in the evaluation methods of the therapeutic effect of diabetic macular edema, such as optical correlation tomography angiography [37,38] . The year 2020 witnessed the largest published number on the treatment of DME throughout the past decade, which may be related to the ranibizumab's patent expired in the United States.…”

Section: Discussionmentioning

confidence: 99%

Treatment of diabetic macular edema: Bibliometric analysis

Wang,

Shen,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose To comprehensively analyze and discuss the publications about treatment of diabetic macular edema (DME) following a bibliometric approach. Methods The publications on treatment of diabetic macular edema from 2014 to 2023 were retrieved from the Web of Science Core Collection (WoSCC) database. We analyzed the publication and citation trend over time and identified highly-cited articles, productive countries, institutions, journals and the most relevant research domains. VOSviewer was used to visualize the mainstream research topics and keywords. Results By analyzing a total of 1081 relevant publications, the number of annual publications showed an increasing trend over the last ten years, with the average growth rate of 15.15%. USA (290/1081), Italy (119/1081), China (110/1081) and Japan (99/1081) were the most productive countries. Retina-The Journal of Retinal and Vitreous Diseases was the most productive journal in this field. Johns Hopkins University (USA, 53/1047), Harvard University (USA, 34/1047), JAEB Center For Health Research (USA, 33/1047) and Assistance Publique Hopitaux Paris (France, 31/1047) were the most productive institutions. The analysis of keywords showed that “diabetic macular edema”, “ranibizumab”, “retinopathy”, “bevacizumab” and “endothelial growth-factor” were the most frequent keywords throughout the entire period. Conclusion This study summarized the recent advances in the treatment on diabetic macular edema. Most studies have focused on the therapeutic effects of anti-VEGF agents on DME. With the deepening of technology and research, more and more reasonable treatment methods will emerge.

show abstract

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema

Cited by 11 publications

References 39 publications

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Treatment of diabetic macular edema: Bibliometric analysis

Contact Info

Product

Resources

About